Skip to main content
Vaccine shows promise for patients with high-risk melanoma

Clinical trials for a vaccine made from a patient's blood and tumor showed promise in high-risk melanoma patients, according to the vaccine's developer, Elios Therapeutics. The vaccine sparks the patient's T-cells and immune system to destroy the cells.

Full Story: